

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Amendments to Claims:**

---

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)

BI

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Newly Added) A method for treatment of diseases influenced by the inhibition of NF- $\kappa$ B production comprising:

administering a composition comprising an R-enantiomer of an arylpropionic acid or a derivative thereof which does not metabolize to CoA thioesters selected from R-flurbiprofen, R-ketoprofen, R-naproxen, R-tiaprofenic acid, and/or R-fenoprofen to a human subject suffering from a disease influenced by the inhibition of NF- $\kappa$ B production,

31 wherein the composition comprises the R-arylpropionic acid or the R-arylpropionic acid derivative in an amount from 100 to 1000 mg/dose.

22. (Newly Added) A method according to claim 21, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is essentially free of S-arylpropionic acids or S-arylpropionic acid derivatives.

23. (Newly Added) A method according to claim 21, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is present as a salt of an alkali metal, an alkaline earth metal, an ammonium, an amino acid, or aluminum

24. (Newly Added) A method according to claim 23, wherein the salt is an amino acid salt selected from the group consisting of a lysinate salt, a megluminate salt, a trometamine salt and an arginate salt.

25. (Newly Added) A method according to claim 21, wherein the composition comprises a medicament.

~~26.~~ (Newly Added) A method according to claim 25, wherein the medicament comprises at least one adjuvant and/or a carrier material.

~~27.~~ (Newly Added) A method according to claim 25, wherein the medicament comprises an orally usable form.

~~28.~~ (Newly Added) A method according to claim 27, wherein the orally usable form comprises a tablet or a dragee.

~~29.~~ (Newly Added) A method according to claim 21, wherein the R-arylpropionic acid or R-arylpropionic acid derivative is used in timed-release form.

~~30.~~ (Newly Added) A method according to claim 29, wherein the timed-release form comprises a rapidly inflowing form.

~~31.~~ (Newly Added) A method according to claim 29, wherein the timed-release form comprises a retardedly inflowing form.

~~32.~~ (Newly Added) A method according to claim 29, wherein the timed-release form comprises a combined rapidly and retardedly inflowing form.

~~33.~~ (Newly Added) A method according to claim 21, wherein the method for treatment of diseases influenced by the inhibition of NF- $\kappa$ B production comprises treatment of pain due to at least one of a rheumatic disease, asthma, a tumor, an immune disease, shock, an inflammatory intestinal disease, radiation damage, arteriosclerosis and rejection reactions after tissue and organ transplantation.

34. (Newly Added) A method according to claim 33, wherein the inflammatory intestinal disease comprise crohn's disease or colitis ulcerosa.